Articles in Scholarly Journals [Incomplete List]

1. Gene Modulatory Effects, Pharmacokinetics, and Clinical Tolerance of Interferon-a1b: A Second Member of the Interferon-a Family
   Clinical Pharmacology & Therapeutics, vol. 81, no. 3, Article ID 6100081, 7 pages, 2007
2. Methylthioadenosine phosphorylase gene deletions are frequently detected by fluorescence in situ hybridization in conventional chondrosarcomas
   Cancer Genetics and Cytogenetics, vol. 166, no. 2, pp. 95–100, 2006
3. Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer
   British Journal of Cancer, vol. 94, no. 10, Article ID 6603099, 6 pages, 2006
4. Journal of Interferon & Cytokine Research, vol. 26, no. 11, pp. 800–803, 2006
5. Phase II Trial of Gemcitabine as First Line Chemotherapy in Patients With Metastatic or Unresectable Soft Tissue Sarcoma
   American Journal of Clinical Oncology, vol. 29, no. 1, pp. 59–61, 2006
6. Efficacy of SSG and SSG/IFNα2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action
   Cancer Chemotherapy and Pharmacology, vol. 60, no. 3, pp. 341–349, 2006
7. Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors
   Investigational New Drugs, vol. 25, no. 3, pp. 211–216, 2006
8. Expression of RASSF1A, an Epigenetically Silenced Tumor Suppressor, Overcomes Resistance to Apoptosis Induction by Interferons
   Cancer Research, vol. 66, no. 5, pp. 2785–2793, 2006
9. Circulating Tumor Cells versus Imaging--Predicting Overall Survival in Metastatic Breast Cancer
   Clinical Cancer Research, vol. 12, no. 21, pp. 6403–6409, 2006
10. Overcoming Resistance to Interferon-Induced Apoptosis of Renal Carcinoma and Melanoma Cells by DNA Demethylation
    Journal of Clinical Oncology, vol. 24, no. 23, pp. 3771–3779, 2006
11. A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors
    Molecular Cancer Therapeutics, vol. 4, no. 6, pp. 948–955, 2005
12. Proteomic identification of proteins conjugated to ISG15 in mouse and human cells
    Biochemical and Biophysical Research Communications, vol. 336, no. 2, pp. 496–506, 2005
13. Review: Milstein Award Lecture: Interferons and Cancer: Where from Here?
    Journal of Interferon Cytokine Research, vol. 25, no. 9, pp. 511–527, 2005
14. Metastatic Uveal Melanoma
    Ophthalmology Clinics of North America, vol. 18, no. 1, pp. 143–150, 2005
15. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis
    Cell Death and Differentiation, vol. 11, no. 8, Article ID 4401416, 8 pages, 2004
16. Reverse Signaling through Membrane-bound Interleukin-15
    Journal of Biological Chemistry, vol. 279, no. 40, pp. 42192–42201, 2004
17. Natural Soluble Interleukin-15R  Is Generated by Cleavage That Involves the Tumor Necrosis Factor- -converting Enzyme (TACE/ADAM17)
    Journal of Biological Chemistry, vol. 279, no. 39, pp. 40368–40375, 2004
18. Retinoic acid-inducible gene-I is induced by interferon-γ and regulates the expression of interferon-γ stimulated gene 15 in MCF-7 cells
    Biochemistry and Cell Biology, vol. 82, no. 3, pp. 401–405, 2004
19. Estrogen and Progesterone Receptor Expression in Uterine and Extrauterine Leiomyosarcomas
    Applied Immunohistochemistry & Molecular Morphology, pp. 338–341, 2004
20. Phase 2 Trial of Interferon-Beta as Second-Line Treatment of Ovarian Cancer, Fallopian Tube Cancer, or Primary Carcinoma of the Peritoneum
    Oncology, vol. 66, no. 5, pp. 343–346, 2004
21. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma
    Melanoma Research, vol. 13, no. 6, pp. 619–626, 2003
22. Journal of Immunotherapy, vol. 26, no. 3, pp. 202–211, 2003
23. IFN-2b and Thalidomide Synergistically Inhibit Tumor-Induced Angiogenesis
    Journal of Interferon Cytokine Research, vol. 23, no. 1, pp. 3–10, 2003
24. Novel Growth and Death Related Interferon-Stimulated Genes (ISGs) in Melanoma: Greater Potency of IFN- Compared with IFN-2
    Journal of Interferon Cytokine Research, vol. 23, no. 12, pp. 745–756, 2003
25. Apoptosis, vol. 8, no. 3, pp. 237–249, 2003
26. High-throughput Immunoblotting. UBIQUITIN-LIKE PROTEIN ISG15 MODIFIES KEY REGULATORS OF SIGNAL TRANSDUCTION
    Journal of Biological Chemistry, vol. 278, no. 19, pp. 16608–16613, 2003
27. Suppression of NF- B Survival Signaling by Nitrosylcobalamin Sensitizes Neoplasms to the Anti-tumor Effects of Apo2L/TRAIL
    Journal of Biological Chemistry, vol. 278, no. 41, pp. 39461–39469, 2003
28. New and modified interferon alfas: Preclinical and clinical data
    Current Oncology Reports, vol. 5, no. 2, pp. 108–113, 2003
29. Identification of X-linked Inhibitor of Apoptosis-associated Factor-1 as an Interferon-stimulated Gene That Augments TRAIL Apo2L-induced Apoptosis
    Journal of Biological Chemistry, vol. 277, no. 32, pp. 28504–28511, 2002
30. Resistance to Interferons in Melanoma Cells Does Not Correlate with the Expression or Activation of Signal Transducer and Activator of Transcription 1 (Stat1)
    Journal of Interferon Cytokine Research, vol. 22, no. 5, pp. 603–613, 2002
31. Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin’s lymphoma treated with interferon alfa (IFN-a2a) plus an anthracycline-based induction regimen
    Leukemia, vol. 15, no. 7, Article ID 2402161, 4 pages, 2001
32. Reducing primary melanoma mortality
    Current Oncology Reports, vol. 2, no. 4, pp. 289–291, 2000
33. Neuropsychological effects of interferon ?-1a in relapsing multiple sclerosis
    Annals of Neurology, vol. 48, no. 6, pp. 885–892, 2000
34. Second-generation interferons for cancer: clinical targets
    Seminars in Cancer Biology, vol. 10, no. 2, pp. 125–144, 2000
35. Pharmaceutical Research, vol. 15, no. 1, pp. 2–3, 1998
36. Pharmaceutical Research, vol. 15, no. 1, pp. 1–1, 1998
37. Investigational New Drugs, vol. 16, no. 3, pp. 259–263, 1998
38. American Journal of Clinical Oncology, vol. 21, no. 5, pp. 509–512, 1998
39. Molecular and Cellular Biochemistry, vol. 167, no. 1-2, pp. 169–177, 1997
40. Effects of tamoxifen and interferon-β or the combination on tumor-induced angiogenesis
    International Journal of Cancer, vol. 71, no. 3, pp. 456–461, 1997
41. Immunoregulatory properties of ISG15, an interferon-induced cytokine
    Proceedings of the National Academy of Sciences, vol. 93, no. 1, pp. 211–215, 1996
42. Modulation of Interferon (IFN)-inducible Gene Expression by Retinoic Acid
    Journal of Biological Chemistry, vol. 271, no. 18, pp. 10508–10514, 1996
43. Hematologic and Immunologic Evaluation of Recombinant Human Interleukin-6 in Patients with Advanced Malignant Disease: Evidence for Monocyte Activation
    Journal of Immunotherapy, vol. 19, no. 3, pp. 231–243, 1996
44. Transcriptional induction of genes by IFN-ß in mouse cells is regulated by a transcription factor similar to human ISGF-3
    Antiviral Research, vol. 25, no. 2, pp. 91–103, 1994
45. Molecular diagnosis and monitoring of leukemia and lymphoma
    Leukemia Research, vol. 17, no. 12, pp. 1073–1078, 1993
46. Prognostic factors in metastatic melanoma
    Cancer, vol. 71, no. 10, pp. 2995–3005, 1993
47. Human recombinant interferon-?SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse
    Breast Cancer Research and Treatment, vol. 25, no. 2, pp. 141–150, 1993
48. Pharmacodynamics of Biological Response In Vivo After Single and Multiple Doses of Interferon?????
    Journal of Immunotherapy, vol. 13, no. 3, pp. 191–200, 1993
49. Inhibitory Effects of Cytokines on Vascular Endothelial Cells: Synergistic Interactions Among Interferon-??, Tumor Necrosis Factor-??, and Interleukin-1
    Journal of Immunotherapy, vol. 12, no. 4, p. 286, 1992
50. Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor
    Cancer, vol. 69, no. 2, pp. 562–571, 1992
51. Interferons: Pleiotropic cellular modulators
    Clinical Immunology and Immunopathology, vol. 62, no. 1, pp. S18–S24, 1992
52. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma
    Investigational New Drugs, vol. 10, no. 4, pp. 337–343, 1992
53. Applications of monoclonal antibodies and recombinant cytokines for the treatment of human colorectal and other carcinomas
    Journal of Surgical Oncology, vol. 48, no. S2, pp. 9–13, 1991
54. Immunological Effects of Levamisole In Vitro
    Journal of Immunotherapy, vol. 10, no. 5, pp. 297–306, 1991
55. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas
    Cancer, vol. 66, no. 5, pp. 862–867, 1990
56. Inhibition of hormone-dependent and independent breast cancer cell growthin vivo andin vitro with the antiestrogen toremifene and recombinant human interferon-a2
    Breast Cancer Research and Treatment, vol. 15, no. 2, pp. 95–101, 1990
57. The appearance of hypodense eosinophils during interleukin-2 treatment
    Journal of Allergy and Clinical Immunology, vol. 85, no. 3, pp. 557–566, 1990
58. Interferons and indoleamine 2,3-dioxygenase: Role in antimicrobial and antitumor effects
    Experientia, vol. 45, no. 6, pp. 535–541, 1989
59. Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The eastern cooperative oncology group (ECOG) experience
    Cancer, vol. 64, no. 2, pp. 484–490, 1989
60. Interferons: Biological and clinical effects
    Seminars in Surgical Oncology, vol. 5, no. 6, pp. 391–401, 1989
61. Effects of interferons in neoplastic diseases of man
    Pharmacology & Therapeutics, vol. 37, no. 2, pp. 213–229, 1988
62. Plasma lipoprotein changes in humans induced by β-interferon
    Atherosclerosis, vol. 67, no. 2-3, pp. 261–267, 1987
63. Assessment of the antigenic response in humans to a recombinant mutant interferon beta
    Journal of Clinical Immunology, vol. 7, no. 5, pp. 365–375, 1987
64. Antiproliferative activity of recombinant interferons alpha and beta for human renal carcinoma cells: Supra-additive activity with elevated temperature or vinblastine
    World Journal of Urology, vol. 3, no. 4, pp. 230–233, 1986
65. Decreases in serum high-density-lipoprotein cholesterol and total cholesterol resulting from naturally produced and recombinant DNA-derived leukocyte interferons
    Metabolism, vol. 33, no. 5, pp. 400–404, 1984
66. Effect of influenza A virus on leukocyte histamine release
    Journal of Allergy and Clinical Immunology, vol. 71, no. 4, pp. 382–388, 1983
67. Effects of levamisole on human natural killer and killer cell activity and production of interferons
    Immunopharmacology, vol. 5, no. 1, pp. 11–18, 1982
68. Augmentation in the infectivity of SV40 virus DNA by amphotericin B methyl ester
    Archives of Virology, vol. 69, no. 2, pp. 161–165, 1981
69. Enhancement in recall antigen responses by frequent, repetitive skin testing with candida, mumps, and streptokinase-streptodornase in 38 normal adults
    Cancer Immunology Immunotherapy, vol. 10, no. 1, pp. 27–31, 1980
70. Recommendations for clinical protocol development and definition of therapeutic response for soft-tissue sarcomas
    Cancer, vol. 46, no. 4, pp. 796–800, 1980
71. Hexamethylmelamine treatment of sarcomas and lymphomas
    Medical and Pediatric Oncology, vol. 3, no. 4, pp. 401–406, 1977
72. Inhibition by streptovaricins of rauscher leukemia virus splenomegaly
    International Journal of Cancer, vol. 14, no. 6, pp. 817–825, 1974
73. SELECTIVE INHIBITION OF VIRAL FUNCTIONS: THE ANTIVIRAL ACTION OF INTERFERON AND STREPTOVARICIN
    Medicine, vol. 51, no. 3, pp. 181–188, 1972
74. VIRAL CHEMOTHERAPY: ITS PROMISE AND PROBLEMS
    Medicine, vol. 51, no. 3, pp. 189–190, 1972
75. DEPRESSION OF INTERFERON PRODUCTION AFTER A.L.S. TREATMENT
    The Lancet, vol. 294, no. 7633, pp. 1307–1308, 1969